BriaCell wins FDA clearance to start Bria-PROS+ prostate cancer trialPUBT·Aug 5 at 06:30 AMBCTXW0.00%BCTX+3.10%
BriaCell publishes investor presentation on Bria-IMT immunotherapy program for metastatic breast cancerPUBT·Jul 21 at 10:28 AMBCTXW0.00%BCTXZ-6.55%
Is CRA International (CRAI) Quietly Redefining Its Oncology Consulting Edge With The Bria-IMT Mandate?Simplywall·Jul 16 at 12:08 PMCRAI+3.26%BCTXW0.00%
BriaCell opens first Canadian Phase 3 trial site at Sunnybrook’s Odette Cancer Centre in TorontoPUBT·Jul 16 at 06:31 AMBCTX+3.10%BCTXW0.00%
BriaCell signs manufacturing deal with FUJIFILM Biotechnologies for Bria-IMT Phase 3 supplyPUBT·Jul 15 at 06:30 AMBCTX+3.10%BCTXW0.00%
BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisitionTradingView·Jun 26 at 03:13 PMBCTXZ-6.55%BCTX+3.10%
BriaCell signs MoU with Uneedle on microneedle delivery for Bria-IMT breast cancer therapyPUBT·Jun 25 at 06:30 AMBCTXW0.00%BCTXZ-6.55%
BriaCell publishes investor presentation on Bria-IMT pivotal Phase 3 metastatic breast cancer programPUBT·Jun 18 at 09:59 PMBCTXZ-6.55%BCTXW0.00%
BriaCell Therapeutics 3Q FY2026: Net loss $(7.16M), EPS $(0.99) — 10-Q SummaryTradingView·Jun 9 at 03:11 PMBCTXW0.00%BCTX+3.10%
North American Morning Briefing: Tech Rally Rolls On as Markets Look Past Fresh U.S.-Iran Strikes -2-MorningStar·Jun 1 at 05:30 AMBCTXW0.00%BBY+2.75%
BriaCell Therapeutics Announces Pricing of Offering | BCTX Stock NewsStockTitan·May 31 at 11:00 AMBCTXZ-6.55%BCTX+3.10%
BriaCell Gains Sixth Position DSMB Recommendation For Phase 3 Breast Cancer Studynasdaq·May 26 at 07:40 AMBCTX+3.10%BCTXW0.00%
